AssayIndex
Incretin analogues and co-agonists

Exenatide

exendin-4 · AC2993 · C184H282N50O60S · monoisotopic 4183.9370 Da. The index holds 36 assay reports on this compound across 8 batches from 6 suppliers.

36 reports8 batchesmedian 98.94 %index spec 98.0 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

Exenatide is not lipidated and elutes early at 14.9 min, which makes it a useful system-suitability compound: it is the index's reference for confirming that a lab's gradient is calibrated, because its retention is insensitive to small organic-phase errors. The single impurity that dominates real lots is Met14 sulfoxide, and its level is a direct read on how the material was handled rather than how it was made. The index therefore reports exenatide sulfoxide separately from total impurities on batch pages, and treats a sulfoxide level above 1.2 % area as a cold-chain finding rather than a synthesis finding. Base peak [M+4H]4+ at m/z 1046.99.

Molecular formula
C184H282N50O60S
Monoisotopic mass
4183.9370Da
Average mass
4186.57Da
Residues
39
Nominal retention (RG-2, 30 min)
14.92min
Retention window
0.40min
Counter-ion as usually shipped
acetate
Typical label claims
2 mg · 5 mg · 10 mg
Analytical difficulty (index scale)
1.05 — straightforward
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

01791358153727163 Exenatide14.92 min · 98.94 % 14.21 same trace · ×200 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative Exenatide trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 98.94 % area at the nominal retention time of 14.92 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 36 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 98.94% n=36
Interquartile range 0.99pp n=36
Minimum 97.84% n=36
Maximum 99.93% n=36
Pass rate vs spec 94.4% n=36
Median recovery vs claim 97.8% n=18
Median water 3.72% n=36
Median |mass error| 2.8ppm n=31
024692.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=097.50–97.75 %: n=097.75–98.00 %: n=298.00–98.25 %: n=298.25–98.50 %: n=598.50–98.75 %: n=698.75–99.00 %: n=599.00–99.25 %: n=299.25–99.50 %: n=599.50–99.75 %: n=499.75–100.00 %: n=5median 98.94 Purity (% area) Reports
Figure 2. Purity distribution across all 36 Exenatide records. Dashed line is this compound's median (98.94 %); the solid vertical is the index acceptance specification for the incretin analogues and co-agonists class (98.0 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

97.798.198.598.999.399.7100.1GL BiochemGL Biochem: Q1 98.38, median 98.53, Q3 98.83, n=9n=9FGPFGP: Q1 98.63, median 98.92, Q3 99.18, n=8n=8TFCTFC: Q1 99.62, median 99.83, Q3 99.93, n=8n=8QSCQSC: Q1 98.78, median 98.94, Q3 99.29, n=7n=7SWBSWB: Q1 99.00, median 99.30, Q3 99.60, n=2n=2KPKP: Q1 97.92, median 98.00, Q3 98.09, n=2n=2 Purity (% area)
Figure 3. Exenatide purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
des-Gly1 truncate (−57 Da)-0.42-57.02197%0.070.62
Trp25 oxidation (+16 Da)-0.71+15.99594%0.190.94
truncated (1-38)-0.55-156.10189%0.071.23
C-terminal free acid (+1 Da)+0.34+0.98486%0.201.30
Met14 sulfoxide (+16 Da)-0.88+15.99581%0.100.80

Degradation pathways

  • Met14 oxidation — the dominant route, and the reason exenatide should be shipped cold
  • C-terminal amide hydrolysis in acidic solution

Full impurity profile, with what each named species implies about the synthesis →

Section 6

Clinical context

Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.

Exenatide's twice-daily and extended-release formulations have been in clinical use since 2005; the EXSCEL outcome trial was reported in NEJM (2017).

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q10n<3—
2024-Q20n<3—
2024-Q31n<3—
2024-Q4899.8399.58–99.93
2025-Q10n<3—
2025-Q2898.9297.91–99.39
2025-Q30n<3—
2025-Q40n<3—
2026-Q11198.4197.84–98.94
2026-Q2798.9498.45–99.48
2026-Q31n<3—

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent Exenatide records of 36.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042500SWBSWB-2603-D6146PeptideMeter2026-Q398.705.31—Supplier-supplied2MARGINAL
AX-2026-041712QSCQSC-2602-P9435Medutest2026-Q299.484.78—Supplier-supplied0PASS
AX-2026-041715QSCQSC-2602-P9435PeptideMeter2026-Q298.945.18—Supplier-supplied0PASS
AX-2026-041716QSCQSC-2602-P9435VendorInvestigate2026-Q298.645.35—Buyer-sourced0PASS
AX-2026-041710QSCQSC-2602-P9435Janoshik2026-Q299.324.84—Supplier-supplied0PASS
AX-2026-041711QSCQSC-2602-P9435Kestrel2026-Q299.264.59—Supplier-supplied1MARGINAL
AX-2026-041714QSCQSC-2602-P9435PeptideMeter2026-Q298.455.10103.4Supplier-supplied0PASS
AX-2026-041713QSCQSC-2602-P9435PeptideMeter2026-Q298.935.58—Supplier-supplied1MARGINAL
AX-2026-043192GL BiochemGLBI-2509-A8203Janoshik2026-Q198.833.48—Supplier-supplied1MARGINAL
AX-2026-043193GL BiochemGLBI-2509-A8203Janoshik2026-Q198.534.0490.1Supplier-supplied1MARGINAL
AX-2026-042991KPKP-2511-W5336Janoshik2026-Q198.173.3196.4Supplier-supplied0PASS
AX-2026-043189GL BiochemGLBI-2509-A8203PeptideMeter2026-Q198.893.14—Supplier-supplied1MARGINAL
AX-2026-042990KPKP-2511-W5336Medutest2026-Q197.843.37—Supplier-supplied1FAIL
AX-2026-043194GL BiochemGLBI-2509-A8203Medutest2026-Q198.583.7697.9Supplier-supplied2MARGINAL
AX-2026-043190GL BiochemGLBI-2509-A8203Nordanalyt2026-Q198.383.85—Buyer-sourced1MARGINAL
AX-2026-043196GL BiochemGLBI-2509-A8203Janoshik2026-Q198.413.63103.0Laboratory-retained1MARGINAL
AX-2026-043191GL BiochemGLBI-2509-A8203PeptideMeter2026-Q198.253.9688.8Laboratory-retained3MARGINAL
AX-2026-043195GL BiochemGLBI-2509-A8203Janoshik2026-Q198.944.02107.4Supplier-supplied1MARGINAL
AX-2026-043204GL BiochemGLBI-2511-M8631Janoshik2026-Q198.218.1894.6Supplier-supplied0FAIL
AX-2025-018935FGPFGP-2504-V9993Janoshik2025-Q299.274.0997.6Supplier-supplied1MARGINAL
AX-2025-018932FGPFGP-2504-V9993Janoshik2025-Q299.153.88—Supplier-supplied2MARGINAL
AX-2025-018936FGPFGP-2504-V9993Medutest2025-Q297.914.11101.0Laboratory-retained1FAIL
AX-2025-018933FGPFGP-2504-V9993Janoshik2025-Q299.113.62—Supplier-supplied1MARGINAL
AX-2025-018931FGPFGP-2504-V9993Janoshik2025-Q298.373.47—Supplier-supplied2MARGINAL
AX-2025-018930FGPFGP-2504-V9993Janoshik2025-Q298.733.8598.3Supplier-supplied1MARGINAL